Back HCV Treatment

HCV Treatment

EASL 2015: Liver Function and Survival Improve after Hepatitis C Treatment with Viekira Pak

Hepatitis C patients treated with AbbVie's Viekira Pak "3D" regimen saw improvements in liver function biomarkers, had better quality of life, and had increased survival compared to untreated people, according to mathematical model studies presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. One model showed that treatment can be cost-effective at all stages of liver disease.

alt

Read more:

EASL 2015: Hepatitis C Treatment May Be Highly Cost-effective for Prisoners in England

Reducing the duration of direct-acting antiviral therapy for hepatitis C will make treatment for prisoners in England highly cost-effective, and could provide an important opportunity for providing access to hepatitis C treatment for people who inject drugs, Natasha Martin from the University of California San Diego reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.

alt

Read more:

EASL 2015: Shortening Triple Therapy to 6 Weeks Is Effective for Some Hepatitis C Patients

Shortening direct-acting antiviral therapy to 6 weeks for easier-to-treat patients without liver cirrhosis does not greatly reduce the efficacy of hepatitis C treatment for people with HCV genotype 1 infection, according to results of a study evaluating grazoprevir, elbasvir, and sofosbuvir (Sovaldi) in short treatment courses. Moreover, for people with HCV genotype 3 but no cirrhosis, an 8-week course of treatment was only marginally less effective than a 12-week course, even though genotype 3 infection is considered harder to treat.

alt

Read more:

Daclatasvir, Asunaprevir, and Beclabuvir Shows High Cure Rates for People with Genotype 1 Hepatitis C

A twice-daily fixed-dose coformulation of daclatasvir, asunaprevir, and beclabuvir taken for 12 weeks cured 91% of genotype 1 chronic hepatitis C patients without liver cirrhosis, and even higher sustained response rates were obtained for people with cirrhosis when ribavirin was added, according to findings from the Phase 3 UNITY studies published in the May 5 issue of JAMA.

alt

Read more:

EASL 2015: Sofosbuvir/ Ledipasvir Cures More Than 90% of People with Hepatitis C Genotypes 4 and 5

An interferon-free regimen of sofosbuvir and ledipasvir (Harvoni) produced sustained virological response rates of 93% for people with HCV genotype 4 and 95% for those with genotype 5, according to a French study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.

alt

Read more: